ATNX - Athenex Inc

-

$undefined

N/A

(N/A)

Athenex Inc NASDAQ:ATNX Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company's current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex's employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina.

Location: 1001 Main St Ste 600, New York, 14203-1009, US | Website: www.athenex.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Short % of Float

5.48%

Insider Ownership

9.73%

Institutional Own.

29.87%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Klisyri (Tirbanibulin ointment) Details
Skin disease/disorder, Actinic keratosis

Approved

Quarterly sales

Oral docetaxel + encequidar Details
Solid tumor/s, Cancer, Prostate cancer

Failed

Discontinued

Oral paclitaxel + encequidar Details
Metastatic breast cancer, Cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued

KUR-501 Details
Neuroblastoma

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Oral Paclitaxel + KEYTRUDA (Pembrolizumab) Details
Non-small cell lung carcinoma, Cancer, Solid tumor/s

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

KUR-502 Details
B-cell malignancies

Failed

Discontinued